Yehuda Carmeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yehuda Carmeli has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
David Schwartz
Infectious Diseases Unit,1 Division of Epidemiology,2 Microbiology Laboratory, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel3
2 shared publicationsEssy Mozaffari
2 shared publicationsGeorge M. Eliopoulos
2 shared publications- Shiri Navon-Venezia
The Department of Molecular Biology, The Faculty of Natural Sciences, Ariel University
2 shared publications Adolf W. Karchmer
1 shared publicationBoris Kuzmenko
Laboratories for Molecular Epidemiology
1 shared publication
Latest Publications
- 1 June 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (6) , 2444-2447
Infection of a Ventriculoatrial Shunt with Phenotypically Variable Staphylococcus epidermidis Masquerading as Polymicrobial Bacteremia Due to Various Coagulase-Negative Staphylococci and Kocuria varians
The diagnosis of bloodstream infection with coagulase-negative staphylococci is frequently based on the isolation of the same organism from more than one blood culture. Phenotypic variation is a common characteristic of pathogenic strains of Staphylococcus epidermidis which may affect species identification by the microbiology laboratory. We describe a patient with a new onset of nephritis and gram-positive bacteremia. Gram-positive cocci grew in multiple blood cultures and were identified by the Vitek 2 system as Kocuria varians , Staphylococcus hyicus , and S. epidermidis . Bacterial isolates grew on blood agar and Congo red agar plates as two distinct morphotypes and exhibited phenotypic variation. Neither morphotype could be identified by the API-Staph assay. Cellular fatty acid analysis identified one of the morphotypes as S. epidermidis but could not identify the other morphotype. All isolates were found to be identical by pulsed-field gel electrophoresis, and both colonial morphotypes were identified as S. epidermidis by 16S ribosomal gene sequencing. Phenotypic variation of S. epidermidis may affect identification to the species level by phenotype-based identification systems. Caution should be exercised when differentiating between true infection and contamination based on strain identification.
- 1 June 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (6) , 2444-2447
Infection of a Ventriculoatrial Shunt with Phenotypically Variable Staphylococcus epidermidis Masquerading as Polymicrobial Bacteremia Due to Various Coagulase-Negative Staphylococci and Kocuria varians
The diagnosis of bloodstream infection with coagulase-negative staphylococci is frequently based on the isolation of the same organism from more than one blood culture. Phenotypic variation is a common characteristic of pathogenic strains of Staphylococcus epidermidis which may affect species identification by the microbiology laboratory. We describe a patient with a new onset of nephritis and gram-positive bacteremia. Gram-positive cocci grew in multiple blood cultures and were identified by the Vitek 2 system as Kocuria varians , Staphylococcus hyicus , and S. epidermidis . Bacterial isolates grew on blood agar and Congo red agar plates as two distinct morphotypes and exhibited phenotypic variation. Neither morphotype could be identified by the API-Staph assay. Cellular fatty acid analysis identified one of the morphotypes as S. epidermidis but could not identify the other morphotype. All isolates were found to be identical by pulsed-field gel electrophoresis, and both colonial morphotypes were identified as S. epidermidis by 16S ribosomal gene sequencing. Phenotypic variation of S. epidermidis may affect identification to the species level by phenotype-based identification systems. Caution should be exercised when differentiating between true infection and contamination based on strain identification.
- Top Cited PapersOpen Access
- 1 June 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (11) , 1433-1437
The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organi
- 1 June 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (11) , 1433-1437
Top Cited PapersOpen AccessThe Impact of Antimicrobial Resistance on Health and Economic Outcomes
Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organi
- Open Access
- 1 January 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (1) , 155-158
Occurrence and Phenotypic Characteristics of Extended-Spectrum β-Lactamases among Members of the Family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests
We assessed the prevalence and phenotypic characteristics of extended-spectrum β-lactamase (ESBL) producers among cefuroxime-resistant (CXM-R) (MIC ≥ 32 μg/ml) members of the family Enterobacteriaceae in our institution. The 438 CXM-R clinical isolates obtained from nonurine sources among inpatients were screened. ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). A difference of ≥5 mm in the size of the zone of inhibition in the presence of CLAV for at least one of the agents was considered representative of the ESBL phenotype: 186 isolates (42.5%) were confirmed as ESBL producers. The isolates tested and the rates of ESBL producers were as follows: Klebsiella spp. ( n = 81), 79%; Proteus spp. ( n = 58), 62%; Escherichia coli ( n = 64), 53%; Enterobacter spp. ( n = 69), 42%; Serratia spp. ( n = 70), 14%; Citrobacter spp. ( n = 25), 24%; Providencia spp. ( n = 21), 24%; Morganella spp. ( n = 41), 5%; and Kluyvera ( n = 3), 0%. The overall sensitivity of isolated ESBL confirmatory tests was 79% for CPD-CLAV, 66% for CTZ-CLAV, and 91% for CTX-CLAV. Sensitivities of CTZ-CLAV confirmatory tests for Klebsiella spp., Proteus spp., E. coli , and Enterobacter spp. were 84, 22, 76, and 62%, respectively, and those for CTX-CLAV were 95, 97, 94, and 83%, respectively. They were 90% for CPD-CLAV and CTZ-CLAV, 95% for CPD-CLAV and CTX-CLAV, and 100% for CTZ-CLAV and CTX-CLAV. ESBL production was highly prevalent among Enterobacteriaceae. Using resistance to CXM as an ESBL screening criterion is a suitable option in high-incidence areas where Klebsiella spp. are not the dominant ESBL producers. This screening criterion may simplify the screening test and improve its sensitivity, although at the price of testing more isolates. The CTX-CLAV combination confirmed ESBL producers better than the CTZ-CLAV combination, with sensitivity varying between species. Combined CTZ-CLAV and CTX-CLAV testing detected all these strains; CPD-CLAV provided no additional benefit.
- 1 January 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (1) , 155-158
Open AccessOccurrence and Phenotypic Characteristics of Extended-Spectrum β-Lactamases among Members of the Family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests
We assessed the prevalence and phenotypic characteristics of extended-spectrum β-lactamase (ESBL) producers among cefuroxime-resistant (CXM-R) (MIC ≥ 32 μg/ml) members of the family Enterobacteriaceae in our institution. The 438 CXM-R clinical isolates obtained from nonurine sources among inpatients were screened. ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). A difference of ≥5 mm in the size of the zone of inhibition in the presence of CLAV for at least one of the agents was considered representative of the ESBL phenotype: 186 isolates (42.5%) were confirmed as ESBL producers. The isolates tested and the rates of ESBL producers were as follows: Klebsiella spp. ( n = 81), 79%; Proteus spp. ( n = 58), 62%; Escherichia coli ( n = 64), 53%; Enterobacter spp. ( n = 69), 42%; Serratia spp. ( n = 70), 14%; Citrobacter spp. ( n = 25), 24%; Providencia spp. ( n = 21), 24%; Morganella spp. ( n = 41), 5%; and Kluyvera ( n = 3), 0%. The overall sensitivity of isolated ESBL confirmatory tests was 79% for CPD-CLAV, 66% for CTZ-CLAV, and 91% for CTX-CLAV. Sensitivities of CTZ-CLAV confirmatory tests for Klebsiella spp., Proteus spp., E. coli , and Enterobacter spp. were 84, 22, 76, and 62%, respectively, and those for CTX-CLAV were 95, 97, 94, and 83%, respectively. They were 90% for CPD-CLAV and CTZ-CLAV, 95% for CPD-CLAV and CTX-CLAV, and 100% for CTZ-CLAV and CTX-CLAV. ESBL production was highly prevalent among Enterobacteriaceae. Using resistance to CXM as an ESBL screening criterion is a suitable option in high-incidence areas where Klebsiella spp. are not the dominant ESBL producers. This screening criterion may simplify the screening test and improve its sensitivity, although at the price of testing more isolates. The CTX-CLAV combination confirmed ESBL producers better than the CTZ-CLAV combination, with sensitivity varying between species. Combined CTZ-CLAV and CTX-CLAV testing detected all these strains; CPD-CLAV provided no additional benefit.
- Open Access
- 28 October 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (19) , 2223-2228
Health and Economic Outcomes of Vancomycin-Resistant Enterococci
ANTIBIOTIC RESISTANCE is a recognized clinical problem and a major public health threat. Infections caused by resistant bacteria are believed to result in severe adverse outcomes (increased mortality, morbidity, and medical care costs).1-4 The reason that antibiotic resistance leads to adverse outcomes is presumably because of an increased likelihood that ineffective or suboptimal antibiotic therapy will be given. Moreover, in some organisms, the development of resistance to all available antibiotics may preclude the effectiveness of any antibiotic regimen.
- 28 October 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (19) , 2223-2228
Open AccessHealth and Economic Outcomes of Vancomycin-Resistant Enterococci
ANTIBIOTIC RESISTANCE is a recognized clinical problem and a major public health threat. Infections caused by resistant bacteria are believed to result in severe adverse outcomes (increased mortality, morbidity, and medical care costs).1-4 The reason that antibiotic resistance leads to adverse outcomes is presumably because of an increased likelihood that ineffective or suboptimal antibiotic therapy will be given. Moreover, in some organisms, the development of resistance to all available antibiotics may preclude the effectiveness of any antibiotic regimen.
- Open Access
- 1 August 2002
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 8 (8) , 802-807
Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus
We conducted a matched case-control study to compare the effect of antecedent treatment with various antibiotics on subsequent isolation of vancomycin-resistant Enterococcus (VRE); 880 in-patients; 233 VRE cases, and 647 matched controls were included. After being matched for hospital location, calendar time, and duration of hospitalization, the following variables predicted VRE positivity: main admitting diagnosis; a coexisting condition (e.g., diabetes mellitus, organ transplant, or hepatobiliary disease); and infection or colonization with methicillin-resistant Staphylococcus aureus or Clostridium difficile within the past year (independent of vancomycin treatment). After controlling for these variables, we examined the effect of various antibiotics. Intravenous treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was positively associated with VRE. In our institution, when we adjusted the data for temporo-spatial factors, patient characteristics, and hospital events, treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was identified as a risk factor for VRE. Vancomycin was not a risk factor for isolation of VRE.
- 1 August 2002
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 8 (8) , 802-807
Open AccessAntecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus
We conducted a matched case-control study to compare the effect of antecedent treatment with various antibiotics on subsequent isolation of vancomycin-resistant Enterococcus (VRE); 880 in-patients; 233 VRE cases, and 647 matched controls were included. After being matched for hospital location, calendar time, and duration of hospitalization, the following variables predicted VRE positivity: main admitting diagnosis; a coexisting condition (e.g., diabetes mellitus, organ transplant, or hepatobiliary disease); and infection or colonization with methicillin-resistant Staphylococcus aureus or Clostridium difficile within the past year (independent of vancomycin treatment). After controlling for these variables, we examined the effect of various antibiotics. Intravenous treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was positively associated with VRE. In our institution, when we adjusted the data for temporo-spatial factors, patient characteristics, and hospital events, treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was identified as a risk factor for VRE. Vancomycin was not a risk factor for isolation of VRE.
- 1 February 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (2P2) , 55S-62S
Use of Insurance Claims Data to Assess Outpatient Antimicrobial Therapy for Gram‐Positive Infections
With the increasing frequency of antibiotic‐resistant gram‐positive infections in the United States, many patients are being treated outside the hospital setting. The majority of studies on the cost of outpatient antimicrobial therapy involve retrospective medical record review or prospective data collection. These methods tend to be expensive and time consuming, and often fail to produce a sufficiently large sample size. Analysis of insurance claims data offers a convenient approach for studying the costs associated with outpatient therapy for gram‐positive infections. To demonstrate this approach, a study of the cost of intravenous vancomycin home care therapy was conducted using claims data from a large insurance company.
- 1 February 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (2P2) , 55S-62S
Use of Insurance Claims Data to Assess Outpatient Antimicrobial Therapy for Gram‐Positive Infections
With the increasing frequency of antibiotic‐resistant gram‐positive infections in the United States, many patients are being treated outside the hospital setting. The majority of studies on the cost of outpatient antimicrobial therapy involve retrospective medical record review or prospective data collection. These methods tend to be expensive and time consuming, and often fail to produce a sufficiently large sample size. Analysis of insurance claims data offers a convenient approach for studying the costs associated with outpatient therapy for gram‐positive infections. To demonstrate this approach, a study of the cost of intravenous vancomycin home care therapy was conducted using claims data from a large insurance company.
- 1 January 1998
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 19 (1) , 38-40
Stool Colonization of Healthcare Workers with Selected Resistant Bacteria
- 1 January 1998
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 19 (1) , 38-40
Stool Colonization of Healthcare Workers with Selected Resistant Bacteria